Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)

Disc Medicine’s bitopertin showed strong Phase 3 results in EPP, targeting FDA submission by year-end.

What the company is saying

Disc Medicine is highlighting topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP), emphasizing that all primary and secondary endpoints were met. The company frames these results as a potential breakthrough, with CEO John Quisel and CMO Will Savage both stressing the clinical impact and the mechanistic rationale for targeting heme synthesis. Principal Investigator Herbert Bonkovsky underscores the novelty of achieving both whole blood PPIX reduction and improvements in disease severity measures. The announcement details statistically significant improvements in time in light without pain, reduction in phototoxic reactions, and quality of life metrics. Disc Medicine states bitopertin was generally well-tolerated, with dizziness (50%) as the most common adverse event, and no events above Grade 3. The company plans to resubmit a New Drug Application to the FDA by the end of 2026, aiming for a decision by mid-2027, and will present further data at a future medical conference. The tone is confident and positions bitopertin as a first-in-class, disease-modifying therapy for EPP.

What the data suggests

The APOLLO Phase 3 trial enrolled 183 patients across the United States, Canada, Europe, and Australia, randomizing them 1:1 to receive 60 mg oral bitopertin or placebo daily for six months. Bitopertin achieved a -41.4% reduction in whole-blood metal-free PPIX versus placebo (p<0.0001), a +12.2 hour increase in average monthly total time in light without pain during month 6 (p=0.0010), and statistically significant improvements across all secondary endpoints, including reduced phototoxic reaction incidence and better patient-reported outcomes. Dizziness was reported in 50% of bitopertin patients but was mild or moderate and transient, with no adverse events above Grade 3. The data package is robust for efficacy and safety, with all endpoints met and clear statistical significance. No financial, revenue, or cost data are disclosed, and the only capital signal is the prior license agreement with Roche. The evidence supports the clinical claims, but the 'breakthrough' and 'first' framing is not directly substantiated by comparative or historical trial data within the release.

Analysis

The announcement presents robust, statistically significant Phase 3 clinical trial results for bitopertin in EPP, with clear numerical evidence supporting efficacy and safety claims. The language is positive and includes phrases such as 'potential breakthrough' and 'first time,' which are somewhat promotional but not unsupported given the trial's outcomes. However, the most material forward-looking claim is the plan to resubmit an NDA by end-2026, with an FDA decision expected by mid-2027—meaning any commercial or financial benefit is at least 18-21 months away. No financial, revenue, or profitability data is disclosed, but as this is a clinical-stage biotech, such absence is normal and not a deficiency. The capital intensity flag is not triggered, as no new capital outlay or spend is announced. The gap between narrative and evidence is moderate: while the topline results are strong, the 'breakthrough' framing is not fully substantiated by comparative or historical data within the release.

Risk flags

• ●Regulatory approval risk remains significant, as the FDA must review and accept the NDA submission, and approval is not guaranteed despite strong trial results. Unexpected safety signals or questions about trial design could delay or prevent approval.
• ●Commercialization risk is present because bitopertin is not yet approved in any jurisdiction, and its market uptake will depend on pricing, reimbursement, and competition with the only currently approved therapy, Scenesse (afamelanotide).
• ●Long timeline to potential revenue means Disc Medicine will likely need to fund operations for at least another 8–21 months before any product launch, increasing exposure to financing or dilution risk if additional capital is required.
• ●The most common adverse event, dizziness (reported in 50% of bitopertin patients), though described as mild or moderate and transient, could affect patient adherence or label warnings if regulators view it as significant.
• ●The claim of being a 'breakthrough' or 'first' is not backed by comparative or historical data in the release, which could lead to heightened expectations that may not be fully justified if subsequent analyses or real-world data do not confirm these results.

Bottom line

Disc Medicine’s APOLLO Phase 3 trial for bitopertin in EPP delivered statistically significant efficacy and safety results, with a -41.4% reduction in PPIX and a +12.2 hour increase in pain-free light exposure. The company is targeting FDA submission by year-end 2026 and a potential decision by mid-2027, so any commercial impact is still at least several quarters away. While the clinical data are strong and all endpoints were met, the announcement does not provide comparative data to existing therapies or financial details. Key risks include regulatory review, commercialization hurdles, and the need to finance operations until approval. Investors should focus on the FDA submission process, any additional data releases, and updates on commercialization plans. The most important takeaway is that bitopertin has cleared a major clinical hurdle, but regulatory and market risks remain before value can be realized.

Announcement summary

(NASDAQ:IRON) Disc Medicine, Inc. announced topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP). The APOLLO trial met all its primary and secondary endpoints. John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine, stated that this represents a potential breakthrough in the science and treatment of EPP. Herbert L. Bonkovsky, M.D., Director of Gastroenterology & Internal Medicine, Professor Emeritus of Medicine at Wake Forest University School of Medicine, and a Principal Investigator of APOLLO, highlighted that this is the first time a potential treatment for EPP has shown robust evidence of whole blood PPIX reduction alongside unequivocal improvement on important measures of disease severity. Will Savage, M.D., Ph.D., Chief Medical Officer of Disc Medicine, emphasized the clinical benefit of a mechanism aimed at reducing the production of PPIX. The APOLLO trial was a randomized, double-blind pivotal Phase 3 study evaluating the safety and efficacy of bitopertin versus placebo in adults and adolescents aged 12 or older with EPP or XLP. The trial enrolled 183 patients across the United States, Canada, Europe, and Australia, stratified by baseline light tolerance and geography, and randomized 1:1 to receive 60 mg oral bitopertin or placebo once daily for 6 months. Bitopertin achieved statistical significance on both co-primary endpoints versus placebo: a reduction in whole-blood metal-free PPIX from baseline of -41.4% versus placebo (p<0.0001), and an increase in average monthly total time in light without pain during month 6 of +12.2 hours versus placebo (p=0.0010). Bitopertin also achieved statistical significance on all secondary endpoints versus placebo, including reduction in incidence rate of phototoxic reactions over the 6-month treatment period (p<0.0001), increase in cumulative total time in light without pain over the 6-month treatment period (p<0.0001), and increase in change from baseline in average daily sunlight exposure time to prodrome versus placebo (p=0.0077, adults only). Additional quality of life benefits were observed, including improved Patient Global Impression of Change (PGIC) score (p<0.0001) and Patient Global Impression of Severity (PGIS) score (p<0.0001). Bitopertin was generally well-tolerated, with dizziness being the most commonly reported treatment emergent adverse event (TEAE) in the bitopertin group (50%), which was mild or moderate and generally transient. There were no TEAEs above Grade 3. Disc Medicine plans to resubmit a New Drug Application (NDA) to the U.S. FDA by the end of 2026, with an FDA decision anticipated by mid-2027. Management will host a corporate webcast on Monday, October 19 at 8:00am EST to discuss the APOLLO topline results and next steps. Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) designed to modulate heme biosynthesis. Disc Medicine obtained global rights to bitopertin under a license agreement from Roche in May 2021. EPP is a rare, debilitating, and potentially life-threatening disease caused by mutations affecting heme biosynthesis, resulting in accumulation of protoporphyrin IX (PPIX). PPIX can result in complications including gallstones, cholestasis, and liver damage in 20-30% of patients and, in extreme cases, liver failure. There is currently no cure for EPP and only one FDA-approved therapy, Scenesse® (afamelanotide).

Disagree with this article?